Axsome Therapeutics (AXSM) FCF Margin (2022 - 2026)
Axsome Therapeutics (AXSM) posted FCF Margin of 10.89% for Q1 2026, down 13.99% sequentially from 9.55% in Q4 2025, and up 2510.0% YoY from 0.42% in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) FCF Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics has reported FCF Margin for 5 years, with the latest figure at 10.89% in Q1 2026.
- Quarterly FCF Margin rose 2510.0% year-over-year to 10.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.02% (up 2783.0% YoY) and the FY2025 annual result came in at 14.7%, up 1866.0% from the prior year.
- FCF Margin eased to 10.89% in Q1 2026 per AXSM's latest filing, from 9.55% in the prior quarter.
- Over five years, FCF Margin peaked at 0.58% in Q3 2025 and troughed at 5246.4% in Q4 2024.
- A 5-year average of 396.3% and a median of 39.22% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin sank 520394 bps in 2024, then soared 523685 bps in 2025.
- Over 5 years, FCF Margin stood at 113.84% in 2022, then jumped by 63 bps to 42.46% in 2023, then sank by 12257 bps to 5246.4% in 2024, then soared by 100 bps to 9.55% in 2025, then retreated by 14 bps to 10.89% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 10.89%, 9.55%, and 0.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -15.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.30% |
| Mar 31, 2026 | -10.89% |
| Dec 31, 2025 | -9.55% |
| Sep 30, 2025 | 0.58% |
| Jun 30, 2025 | -21.62% |
| Mar 31, 2025 | -35.99% |
| Dec 31, 2024 | -5,246.40% |
| Sep 30, 2024 | -17.87% |
| Jun 30, 2024 | -34.60% |
| Mar 31, 2024 | -71.42% |
| Dec 31, 2023 | -42.46% |
| Sep 30, 2023 | -93.30% |
| Jun 30, 2023 | -118.81% |
| Mar 31, 2023 | -6.23% |
| Dec 31, 2022 | -113.84% |
| Sep 30, 2022 | -135.49% |
| Jun 30, 2022 | -382.97% |